| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| ln Vitro |
Peroxidases are a broad family of isoenzymes that are present in nearly all living things. These enzymes usually have molecular weights between 35 and 100 Kd and contain heme. Compared to plant peroxidases, mammalian peroxidases are substantially bigger proteins (576-738 amino acids). Peroxidase's gene sites vary across chromosomes, and the enzyme can exist in monomers, dimers, or tetramers. In certain organs, tissues, cells, and sub-cells, peroxidase exhibits certain distribution patterns and carries out particular functions [1].
|
|---|---|
| References | |
| Additional Infomation |
Moxinositol has been used in clinical trials for the treatment of various diseases, including lymphoma, urothelial carcinoma, relapsed/refractory myelodysplastic syndromes, and metastatic leiomyosarcoma. Moxinositol is a rationally designed, orally effective, class I selective small-molecule 2-aminobenzamide HDAC inhibitor with potential antitumor activity. Moxinositol binds to and inhibits the activity of class I HDAC subtypes (especially HDAC 1, 2, and 3), which may lead to epigenetic alterations in tumor cells, resulting in tumor cell death. Although the exact mechanism is not fully elucidated, tumor cell death may occur through induction of apoptosis, differentiation, cell cycle arrest, inhibition of DNA repair, upregulation of tumor suppressor factors, downregulation of growth factors, oxidative stress, and autophagy. Overexpression of class I HDAC 1, 2, and 3 has been found in many tumors and is associated with poor prognosis.
Mechanism of Action Moxinositol is a novel isoform-selective inhibitor of histone deacetylases (HDACs). HDAC inhibitors exert their effects by activating abnormally switched-off tumor suppressor genes, which are natural defense mechanisms against cancer. Therefore, we hypothesize that specific inhibition of cancer-associated HDACs using moxinositol may restore normal cellular function and reduce or inhibit tumor growth. Pharmacodynamics All HDAC inhibitors induce excessive histone H3 acetylation, which is associated with inhibiting cell proliferation, inducing cell differentiation, and apoptosis. |
| Molecular Formula |
C23H20N6O
|
|---|---|
| Molecular Weight |
396.4445
|
| Exact Mass |
50
|
| CAS # |
9003-99-0
|
| PubChem CID |
9865515
|
| Appearance |
Yellow to brown solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
78.5ºC
|
| Melting Point |
-114.1ºC
|
| Index of Refraction |
1.376
|
| LogP |
0.03
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
538
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4
|
| InChi Key |
HRNLUBSXIHFDHP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)
|
| Chemical Name |
N-(2-aminophenyl)-4-[[(4-pyridin-3-ylpyrimidin-2-yl)amino]methyl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~33.33 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5224 mL | 12.6122 mL | 25.2245 mL | |
| 5 mM | 0.5045 mL | 2.5224 mL | 5.0449 mL | |
| 10 mM | 0.2522 mL | 1.2612 mL | 2.5224 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT03220477
Conditions:Lung CancerLink: https://clinicaltrials.gov/ct2/show/NCT04299113
Conditions:RhabdomyosarcomaLink: https://clinicaltrials.gov/ct2/show/NCT02954991
Conditions:Carcinoma, Non-Small-Cell Lung
Title:Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Status:Terminated
updateDate:2024-03-08
Ctid:NCT02282358
Link: https://clinicaltrials.gov/ct2/show/NCT02282358
Conditions:Lymphoma|Relapsed and Refractory|Diffuse Large B-Cell Lymphoma and Follicular LymphomaLink: https://clinicaltrials.gov/ct2/show/NCT02805660
Conditions:Advanced CancerLink: https://clinicaltrials.gov/ct2/show/NCT02303262
Conditions:Metastatic LeiomyosarcomaLink: https://clinicaltrials.gov/ct2/show/NCT02993991
Conditions:Squamous Cell Carcinoma, Head And Neck|Squamous Cell Carcinoma Mouth|Resectable Squamous Cell Carcinoma of Oral CavityLink: https://clinicaltrials.gov/ct2/show/NCT02018926
Conditions:Myelodysplastic SyndromeLink: https://clinicaltrials.gov/ct2/show/NCT02236195
Conditions:Urothelial CarcinomaLink: https://clinicaltrials.gov/ct2/show/NCT00358982
Conditions:Hodgkin's LymphomaLink: https://clinicaltrials.gov/ct2/show/NCT00359086
Conditions:LymphomaLink: https://clinicaltrials.gov/ct2/show/NCT00374296
Conditions:Myelogenous Leukemia, Acute|Myelodysplastic SyndromesLink: https://clinicaltrials.gov/ct2/show/NCT00372437
Conditions:TumorsLink: https://clinicaltrials.gov/ct2/show/NCT00431873
Conditions:Lymphocytic Leukemia, ChronicLink: https://clinicaltrials.gov/ct2/show/NCT00324220
Conditions:Myelodysplastic Syndrome|Acute Myelogenous LeukemiaLink: https://clinicaltrials.gov/ct2/show/NCT00666497
Conditions:Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS)Link: https://clinicaltrials.gov/ct2/show/NCT00324194
Conditions:Leukemia|Myelodysplastic SyndromesLink: https://clinicaltrials.gov/ct2/show/NCT00324129
Conditions:Leukemia|Myelodysplastic SyndromesLink: https://clinicaltrials.gov/ct2/show/NCT00323934
Conditions:Tumors|Non Hodgkin's LymphomaProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
